An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study

Neurology

Volumn 62, Issue 12, 2004, Pages 2277-2282

  Sundström, Peter ^a,d   Juto, P ^a   Wadell, G ^a   Hallmans, G ^b   Svenningsson, A ^a   Nystrom L ^b   Dillner, J ^c   Forsgren, L ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Department of Neurology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN EBNA1; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN HERPESVIRUS 6; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MEASLES VIRUS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RISK ASSESSMENT; RISK FACTOR; SERUM; SWEDEN; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 2942752168     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000130496.51156.D7     Document Type: Article

References (33)

1. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996;347:1728-1730.
2. Riise T, Gronning M, Klauber MR, Barrett-Connor E, Nyland H, Albrektsen G. Clustering of residence of multiple sclerosis patients at age 13 to 20 years in Hordaland, Norway. Am J Epidemiol 1991;133:932-939.
3. Gilden DH. Viruses and multiple sclerosis. JAMA 2001;286:3127-3129.
4. Levin MC, Lee SM, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 2002;8:509-513.
5. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001;286:3083-3088.
6. Levin LI, Munger KL, Rubertone MV, et al. Multiple sclerosis and Epstein-Barr virus. JAMA 2003;289:1533-1536.
7. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000;11:220-224.
8. Epstein MA. Infectious mononucleosis. Encyclopedia of life sciences. London: Nature Publishing Group, 1999. Available at: http://www.els.net
9. Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS 2001;109:401-411.
10. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: an emerging pathogen. Emerg Infect Dis 1999;5:353-366.
11. Koskiniemi M, Rantalaiho T, Piiparinen H, et al. Infections of the central nervous system of suspected viral origin: a collaborative study from Finland. J Neurovirol 2001;7:400-408.
12. Adams JM, Imagawa DT. Measles antibodies in multiple sclerosis. Proc Soc Exp Biol Med 1962;111:562-566.
13. Sever RL, Reed D, Kurtzke JF, Huebner RJ, Kurland LT. A note on virus antibodies in patients with multiple sclerosis. In: Alter M, Kurtzke JF, eds. The epidemiology of multiple sclerosis. Springfield, IL: Charles C Thomas Publisher, 1968;107-109.
14. Sundström P, Nyström L, Forsgren L. Prevalence of multiple sclerosis in Västerbotten County in northern Sweden. Acta Neurol Scand 2001;103:214-218.
15. Sundström P, Nyström L, Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Västerbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2003;74:29-32.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
18. Juto P, Settergren B. Specific serum IgA, IgG and IgM antibody determination by a modified indirect ELISA-technique in primary and recurrent herpes simplex virus infection. J Virol Methods 1988;20:45-55.
19. Linde A, Andersson J, Lundgren G, Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol 1987;21:109-121.
20. Bray PF, Culp KW, McFarlin DE, Panitch HS, Torkelson RD, Schlight JP. Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. Neurology 1992;42:278-282.
21. Bray PF, Luka J, Culp KW, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992;42:1798-1804.
22. Lang HL, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:940-943.
23. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
24. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2:1221-1225.
25. Sharipo A, Imreh M, Leonchiks A, Imreh S, Masucci MG. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 1998;4:939-944.
26. Mayo I, Arribas J, Villoslada P, et al. The proteasome is a major autoantigen in multiple sclerosis. Brain 2002;125:2658-2667.
27. Rhodes G, Carson DA, Valbracht J, Houghten R, Vaughan JH. Human immune responses to synthetic peptides from the Epstein-Barr nuclear antigen. J Immunol 1985;134:211-216.
28. Blaschke S, Schwarz G, Moneke D, Binder L, Muller G, Reuss-Borst M. Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol 2000;27:866-873.
29. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001;44:1122-1126.
30. Massa M, Mazzoli F, Pignatti P, et al. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2721-2729.
31. Mahler M, Mierau R, Schlumberger W, Bluthner M. A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1. J Mol Med 2001;79:722-731.
32. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol 2003;53:189-197.
33. Fogdell-Hahn A, Soldan SS, Jacobson S. Association of chronic progressive neurological disease and ubiquitous viral agents: lessons from human herpesvirus 6 and multiple sclerosis. Mol Psychiatry 2002;7(suppl 2):S29-31.